cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.25060211
title: Supplementary Material for: Association of Cancer and Its Interaction with Conventional Risk Factors on Cardiovascular Disease Risk

description: Introduction We sought to examine the association of cancer history with the incidence of individual cardiovascular disease events and to clarify whether the history of cancer modifies the relationship between conventional cardiovascular risk factors and incident cardiovascular disease. 
Methods This retrospective cohort study used the JMDC Claims Database, including 3,531,683 individuals. The primary endpoint was the composite cardiovascular disease outcome, which included myocardial infarction, angina pectoris, stroke, heart failure, and atrial fibrillation. 
Results During a follow-up, 144,162 composite endpoints were recorded. Individuals with a history of cancer had a higher risk of developing composite cardiovascular disease events (HR 1.26, 95% CI 1.22-1.29). The HRs for myocardial infarction, angina pectoris, stroke, heart failure, and atrial fibrillation were 1.11 (95% CI 0.98-1.27), 1.15 (95% CI 1.10-1.20), 1.11 (95% CI 1.05-1.18), 1.39 (95% CI 1.34-1.44), and 1.22 (95% CI 1.13-1.32), respectively. Individuals who required chemotherapy for cancer had a higher risk of developing cardiovascular disease. Although conventional risk factors (e.g., overweight/obesity, hypertension, and diabetes) were associated with incident composite cardiovascular disease even in individuals with a history of cancer, the total population-attributable fractions of conventional risk factors were less in individuals with a history of cancer. 
Conclusion Individuals with a history of cancer (particularly those requiring chemotherapy) have a higher risk of cardiovascular disease. Traditional risk factors are important in the development of cardiovascular disease in individuals with and without a history of cancer. In individuals with a history of cancer, however, the total population-attributable fractions of conventional risk factors decreased.
DOI: 10.5517/ccdc.csd.cc2hcrbz
title: CCDC 2305201: Experimental Crystal Structure Determination

description: Related Article: Atheer M. Madlool, Ahmed Alwaaly, Casey M. Dixon, Paul G. Waddell, William Clegg, Michael R. Probert, Ross W. Harrington, Keith Izod|2024|Organometallics|43|164|doi:10.1021/acs.organomet.3c00468
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2hcrc0
title: CCDC 2305202: Experimental Crystal Structure Determination

description: Related Article: Atheer M. Madlool, Ahmed Alwaaly, Casey M. Dixon, Paul G. Waddell, William Clegg, Michael R. Probert, Ross W. Harrington, Keith Izod|2024|Organometallics|43|164|doi:10.1021/acs.organomet.3c00468
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.34740/kaggle/dsv/7477746
title: OnlineFree
DOI: 10.34740/kaggle/dsv/7477745
title: AutoXGB
DOI: 10.5517/ccdc.csd.cc2hjf8r
title: CCDC 2309694: Experimental Crystal Structure Determination

description: Related Article: Debjyoti Pal, Avijit Mondal, Rajashri Sarmah, Dipankar Srimani|2024|Org.Lett.|26|514|doi:10.1021/acs.orglett.3c03944
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2hjf9s
title: CCDC 2309695: Experimental Crystal Structure Determination

description: Related Article: Debjyoti Pal, Avijit Mondal, Rajashri Sarmah, Dipankar Srimani|2024|Org.Lett.|26|514|doi:10.1021/acs.orglett.3c03944
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5281/zenodo.10566301
title: Characterization of sequence-defined polymers by NMR
DOI: 10.5281/zenodo.10566302
title: Characterization of sequence-defined polymers by NMR
DOI: 10.25919/3n72-k393
title: CSIRO Mafic-Ultramafic Geochemical Dataset

description: This dataset includes whole-rock geochemical (public) processed data collected through CSIRO research projects from the mid-1980s to 2021. It represents information over 5300 samples, primarily from the Archean of Western Australia, with a heavy bias towards komatiites and immediately associated rocks and nickel sulphide ores. Most of the data were collected as part of the research projects exploring magmatic sulphide nickel-copper ore deposits. The dataset also includes samples from mafic-ultramafic intrusive rocks in the Halls Creek and Albany-Fraser orogens. 

The dataset has been used in several review publications, as well as in a large number of publications on specific localities. The prominent review publications also draw extensively on other public datasets such as GeoROC and PetDB; for further information, see Related Links.

We envisage the collection as an interrogation tool for all subsequent Nickel-related projects in Australia.

The whole dataset can be downloaded as a CSV file (see 'Files' section). Alternatively, you can download the same dataset by a specific area using the Exploration Toolkit data portal at https://data.exploration.tools/
DOI: 10.6084/m9.figshare.24746493.v1
title: Sequences of 120 metagenome-assembled genomes

description: Sequences of 120 metagenome-assembled genomes
DOI: 10.6084/m9.figshare.24746493
title: Sequences of 120 metagenome-assembled genomes

description: Sequences of 120 metagenome-assembled genomes
DOI: 10.34740/kaggle/dsv/7477738
title: LUFlow Network Intrusion Detection Data Set
DOI: 10.5281/zenodo.8311382
title: [Supplementary Information] Same product, different score: how methodological differences affect EPD results

description: This is the supplementary information related to the manuscript - "ame product, different score: how methodological differences affect EPD results" . The purpose of this study to analyse the causes for inconsistency and the consequences in terms of difference in the results across the Life Cycle Assessment (LCA) models underlying the EPDs.


The supplementary information consists of three files:


SI 1 - Details on the choice of Nordic programme operators who publish product category rules and product specific rules. This documents further includes the details of the life inventory developed to perform the LCA of a triple glazed window using the rule sets published by different programme operators.


SI 2 - Life cycle inventory data for all scenarios considered in this study in machine readable format 


SI 3 - Life cycle impact assessment for all scenarios using EN 15804 + A2 Method V1.02 / EF 3.0 normalization and weighting set.
DOI: 10.17188/1317167
title: Materials Data on RbAgO2 by Materials Project

description: RbAgO2 crystallizes in the orthorhombic Cmcm space group. The structure is three-dimensional. Rb1+ is bonded in a 6-coordinate geometry to six equivalent O2- atoms. There are two shorter (2.84 Å) and four longer (3.04 Å) Rb–O bond lengths. Ag3+ is bonded in a rectangular see-saw-like geometry to four equivalent O2- atoms. All Ag–O bond lengths are 2.04 Å. O2- is bonded to three equivalent Rb1+ and two equivalent Ag3+ atoms to form a mixture of distorted face, edge, and corner-sharing ORb3Ag2 trigonal bipyramids.
DOI: 10.17188/1317174
title: Materials Data on KAgO2 by Materials Project

description: KAgO2 crystallizes in the orthorhombic Cmcm space group. The structure is three-dimensional. K1+ is bonded in a 6-coordinate geometry to six equivalent O2- atoms. There are two shorter (2.70 Å) and four longer (2.88 Å) K–O bond lengths. Ag3+ is bonded in a rectangular see-saw-like geometry to four equivalent O2- atoms. There are two shorter (2.03 Å) and two longer (2.04 Å) Ag–O bond lengths. O2- is bonded to three equivalent K1+ and two equivalent Ag3+ atoms to form a mixture of distorted edge, face, and corner-sharing OK3Ag2 trigonal bipyramids.
DOI: 10.5285/f3c482e3-245e-36a5-e044-000b5de50f38
title: AMT20 (JC053) micro-molar nutrient measurements from CTD bottle samples

description: This dataset consists of 669 measurements of micromolar nutrient concentrations made on samples collected during the Atlantic Meridional Transect programme cruise 20 (AMT20 JC053) between 14th October and 21st November 2010. The cruise track between UK and Chile passed through both north and south Atlantic gyres. This dataset contributes to the AMT time-series of core oceanographic measurements along an north-south transect of the Atlantic Ocean. Samples were collected on a daily basis at 10 to 12 depths in the upper 300m using a CTD rosette with 24 x 20l OTE (Ocean Test Equipment) bottles. Samples were analysed within 1-2 hours of collection for 'nitrate+nitrite', nitrite, phosphate and silicate using a 5-channel Bran and Luebbe AAIII segmented flow autoanalyser. The analytical chemical methodologies used were according to Brewer and Riley (1965) for nitrate, Grasshoff (1976) for nitrite and Kirkwood (1989) for phosphate and silicate. Silicate data were only included from one station as for many of the samples the silicate values were considered suspect by the originator and not submitted.
DOI: 10.15151/esrf-es-931197247
title: Structural analysis of historical materials

description: This proposal aims at implementing a new access route to the ESRF structural analysis capacities for the Heritage Science community. The upgrade to the ESRF-EBS was the triggering element to propose a single block allocation group (BAG). After discussion with multiple interested research teams, it was decided to target two complementary analytical configurations at the ESRF: High angular resolution XRD (ID22) and High lateral resolution XRD (ID13). The combination of these two beamlines generates precious clues on the origin, processing and degradation of historical materials. The new analytical capacities of the EBS, combined with an optimized access route is expected to increase the output of the Cultural Heritage community, to reinforce a scientific network of expert users structured around the ESRF, and to initiate new European collaborations in Heritage Science.
DOI: 10.17188/1196748
title: Materials Data on ZnO by Materials Project

description: ZnO is Wurtzite structured and crystallizes in the hexagonal P6_3mc space group. The structure is three-dimensional. Zn2+ is bonded to four equivalent O2- atoms to form corner-sharing ZnO4 tetrahedra. There are three shorter (2.00 Å) and one longer (2.01 Å) Zn–O bond lengths. O2- is bonded to four equivalent Zn2+ atoms to form corner-sharing OZn4 tetrahedra.
DOI: 10.48329/9dc0-hc62
title: CPRD GOLD May 2022

description: The CPRD GOLD database contains longitudinal routinely-collected electronic health records (EHR data) from UK primary care practices using Vision® general practice patient management software. The database captures information on demographic characteristics; diagnoses and symptoms; drug exposures; vaccination history; laboratory tests; and referrals to hospital and specialist care. Access to anonymised data from CPRD is subject to a full licence agreement containing detailed terms and conditions of use. Anonymised patient datasets can be extracted for researchers against specific study specifications, following protocol approval. Further information is available at https://www.cprd.com/data-access.
DOI: 10.5281/zenodo.7082168
title: A computational method for predicting the most likely evolutionary trajectories in the stepwise accumulation of resistance mutations

description: Supporting information dataset for <em>A computational method for predicting the most likely evolutionary trajectories in the stepwise accumulation of resistance mutations, </em>including Flex ddG binding free energy predictions, epistasis calculations, pathway probabilities, Rosetta files and structural files.
DOI: 10.5281/zenodo.10566358
title: Characterization of sequence-defined polymers by GPC
DOI: 10.5281/zenodo.10566359
title: Characterization of sequence-defined polymers by GPC
DOI: 10.15151/esrf-es-1452845656
title: Practicals for L3 and M1 UGA students

description: beam alignment will be performed and reference samples will be measured during this practicals
DOI: 10.5281/zenodo.10566319
title: Akıl Zeka Antizeka, Einstein İzafiyet, Zamanda Yolculuk, Işık Hızı, Melek Hızı

description: Akıl Zeka Antizeka, Einstein İzafiyet, Zamanda Yolculuk, Işık Hızı, Melek Hızı hakkında doğru bilgilere dayalı sıhhatli yorumlar. Önyargılar ve peşin hükümlülükler ilmin-bilimin önündeki en büyük engellerdir.
DOI: 10.5281/zenodo.10566320
title: Akıl Zeka Antizeka, Einstein İzafiyet, Zamanda Yolculuk, Işık Hızı, Melek Hızı

description: Akıl Zeka Antizeka, Einstein İzafiyet, Zamanda Yolculuk, Işık Hızı, Melek Hızı hakkında doğru bilgilere dayalı sıhhatli yorumlar. Önyargılar ve peşin hükümlülükler ilmin-bilimin önündeki en büyük engellerdir.
DOI: 10.6084/m9.figshare.25047791.v2
title: MEE DatasetB

description: DatasetB
DOI: 10.6084/m9.figshare.25047791
title: MEE DatasetB

description: DatasetB
DOI: 10.6084/m9.figshare.25047791.v1
title: MEE DatasetB

description: DatasetB
DOI: 10.6084/m9.figshare.25060244
title: Supplementary Material for: Association of Cancer and Its Interaction with Conventional Risk Factors on Cardiovascular Disease Risk

description: Introduction We sought to examine the association of cancer history with the incidence of individual cardiovascular disease events and to clarify whether the history of cancer modifies the relationship between conventional cardiovascular risk factors and incident cardiovascular disease. 
Methods This retrospective cohort study used the JMDC Claims Database, including 3,531,683 individuals. The primary endpoint was the composite cardiovascular disease outcome, which included myocardial infarction, angina pectoris, stroke, heart failure, and atrial fibrillation. 
Results During a follow-up, 144,162 composite endpoints were recorded. Individuals with a history of cancer had a higher risk of developing composite cardiovascular disease events (HR 1.26, 95% CI 1.22-1.29). The HRs for myocardial infarction, angina pectoris, stroke, heart failure, and atrial fibrillation were 1.11 (95% CI 0.98-1.27), 1.15 (95% CI 1.10-1.20), 1.11 (95% CI 1.05-1.18), 1.39 (95% CI 1.34-1.44), and 1.22 (95% CI 1.13-1.32), respectively. Individuals who required chemotherapy for cancer had a higher risk of developing cardiovascular disease. Although conventional risk factors (e.g., overweight/obesity, hypertension, and diabetes) were associated with incident composite cardiovascular disease even in individuals with a history of cancer, the total population-attributable fractions of conventional risk factors were less in individuals with a history of cancer. 
Conclusion Individuals with a history of cancer (particularly those requiring chemotherapy) have a higher risk of cardiovascular disease. Traditional risk factors are important in the development of cardiovascular disease in individuals with and without a history of cancer. In individuals with a history of cancer, however, the total population-attributable fractions of conventional risk factors decreased.
DOI: 10.5281/zenodo.10566360
title: Comprehensive analysis of coupled proline cis-trans states in bradykinin using omegaBP-REMD simulations

description: Coordinates in PDB format of configurations in clusters 1, 2 and 3 analyzed in the corresponding paper by Kienlein et al.
DOI: 10.5281/zenodo.10566361
title: Comprehensive analysis of coupled proline cis-trans states in bradykinin using omegaBP-REMD simulations

description: Coordinates in PDB format of configurations in clusters 1, 2 and 3 analyzed in the corresponding paper by Kienlein et al.
DOI: 10.6084/m9.figshare.25060244.v1
title: Supplementary Material for: Association of Cancer and Its Interaction with Conventional Risk Factors on Cardiovascular Disease Risk

description: Introduction We sought to examine the association of cancer history with the incidence of individual cardiovascular disease events and to clarify whether the history of cancer modifies the relationship between conventional cardiovascular risk factors and incident cardiovascular disease. 
Methods This retrospective cohort study used the JMDC Claims Database, including 3,531,683 individuals. The primary endpoint was the composite cardiovascular disease outcome, which included myocardial infarction, angina pectoris, stroke, heart failure, and atrial fibrillation. 
Results During a follow-up, 144,162 composite endpoints were recorded. Individuals with a history of cancer had a higher risk of developing composite cardiovascular disease events (HR 1.26, 95% CI 1.22-1.29). The HRs for myocardial infarction, angina pectoris, stroke, heart failure, and atrial fibrillation were 1.11 (95% CI 0.98-1.27), 1.15 (95% CI 1.10-1.20), 1.11 (95% CI 1.05-1.18), 1.39 (95% CI 1.34-1.44), and 1.22 (95% CI 1.13-1.32), respectively. Individuals who required chemotherapy for cancer had a higher risk of developing cardiovascular disease. Although conventional risk factors (e.g., overweight/obesity, hypertension, and diabetes) were associated with incident composite cardiovascular disease even in individuals with a history of cancer, the total population-attributable fractions of conventional risk factors were less in individuals with a history of cancer. 
Conclusion Individuals with a history of cancer (particularly those requiring chemotherapy) have a higher risk of cardiovascular disease. Traditional risk factors are important in the development of cardiovascular disease in individuals with and without a history of cancer. In individuals with a history of cancer, however, the total population-attributable fractions of conventional risk factors decreased.
DOI: 10.14469/hpc/13690
title: Wilkinson catalyst, phosphine, Remove agostic, rotate methyl -

description: Gaussian 16 (C01) calculation
DOI: 10.14278/rodare.2696
title: Data publication: The fate of fluvially-deposited organic carbon during transient floodplain storage

description: The data set contains all relevant luminescence measurement data used in the corresponding article: Scheingross et al. 2021. The fate of fluvially-deposited organic carbon during transient floodplain storage. EPSL 561, 116822, doi: 10.1016/j.epsl.2021.116822.
DOI: 10.14278/rodare.2695
title: Data publication: The fate of fluvially-deposited organic carbon during transient floodplain storage

description: The data set contains all relevant luminescence measurement data used in the corresponding article: Scheingross et al. 2021. The fate of fluvially-deposited organic carbon during transient floodplain storage. EPSL 561, 116822, doi: 10.1016/j.epsl.2021.116822.
DOI: 10.5281/zenodo.10420685
title: MYC-targeting by OMO-103 in solid tumours: a phase 1 trial

description: MYC is a ‘most wanted’ target in cancer therapy and it coordinates key transcriptional programs in tumour development and maintenance. It has, however, long been considered undruggable. OMO-103 is a MYC inhibitor consisting of a 91 amino acid mini-protein. Here we present results from a Phase 1 study of OMO-103 in advanced solid tumours, to examine safety and tolerability as primary outcomes, and pharmacokinetics, RP2D and preliminary signs of activity as secondary ones. A classical 3+3 design was used for dose escalation of weekly intravenous, single agent OMO-103 administration in 21-day cycles, encompassing 6 dose levels (DLs). A total of 22 patients were enrolled, with treatment maintained until disease progression. The most common adverse events were grade 1 infusion-related reactions occurring in 10 patients. 1 dose-limiting toxicity occurred at DL5. Pharmacokinetics showed non-linearity, with tissue saturation signs at DL5, and a terminal half-life in serum of 40 hours. Of the 19 patients evaluable for response, 12 reached the pre-defined 9-week timepoint to assess drug anti-tumour activity, and 8 of those showed stable disease by computed tomography. 1 patient defined as stable disease by RECIST showed a 49% reduction of total tumour volume at best response. Transcriptomic analysis supported target engagement in tumour biopsies. In addition, we identified soluble factors that are potential pharmacodynamic and predictive response markers. Based on all these data, the recommended Phase 2 dose was determined as DL5 (6.48 mg/kg). ClinicalTrials.gov identifier: NCT04808362.
DOI: 10.5281/zenodo.10420686
title: MYC-targeting by OMO-103 in solid tumours: a phase 1 trial

description: MYC is a ‘most wanted’ target in cancer therapy and it coordinates key transcriptional programs in tumour development and maintenance. It has, however, long been considered undruggable. OMO-103 is a MYC inhibitor consisting of a 91 amino acid mini-protein. Here we present results from a Phase 1 study of OMO-103 in advanced solid tumours, to examine safety and tolerability as primary outcomes, and pharmacokinetics, RP2D and preliminary signs of activity as secondary ones. A classical 3+3 design was used for dose escalation of weekly intravenous, single agent OMO-103 administration in 21-day cycles, encompassing 6 dose levels (DLs). A total of 22 patients were enrolled, with treatment maintained until disease progression. The most common adverse events were grade 1 infusion-related reactions occurring in 10 patients. 1 dose-limiting toxicity occurred at DL5. Pharmacokinetics showed non-linearity, with tissue saturation signs at DL5, and a terminal half-life in serum of 40 hours. Of the 19 patients evaluable for response, 12 reached the pre-defined 9-week timepoint to assess drug anti-tumour activity, and 8 of those showed stable disease by computed tomography. 1 patient defined as stable disease by RECIST showed a 49% reduction of total tumour volume at best response. Transcriptomic analysis supported target engagement in tumour biopsies. In addition, we identified soluble factors that are potential pharmacodynamic and predictive response markers. Based on all these data, the recommended Phase 2 dose was determined as DL5 (6.48 mg/kg). ClinicalTrials.gov identifier: NCT04808362.
DOI: 10.15151/esrf-es-1057385801
title: XRD of water ice above 200 GPa under variable P-T conditions: revealing a structural complexity at planetary interiors pressures.

description: This proposal is a continuation of proposal HC-4677 which aimed at measuring the boundary line between bcc insulating and fcc-superionic (fcc-SI) phases of ice. A sample assembly with two boron-doped diamond absorbers has been optimized and it enabled a controlled laser heating of the ice sample up to 200 GPa. A negative slope for the bcc to fcc-SI transition and a metastable quenched fcc-SI phase at ambient temperature have been observed. That hints to the stability of the fcc-SI phase below 1000K by going to 300 GPa. Also, compact phases with greater packing density than bcc should be observed by compressing water ice up to 400 GPa at 300K. We plan to continue the exploration of the detailed structural properties of dense water ice above 200 GPa. These are very challenging measurements of great impact to model planetary interiors of Uranus, Neptune
and other ice giant exoplanets.